PNTUnknown
POINT Biopharma Global Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for POINT Biopharma Global Inc. (PNT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PNT insiders buying or selling?
POINT Biopharma Global Inc. insiders reported no open-market purchases or sales in the last 12 months. Since May 2022, Trabud has recorded 9 Form 4 filings for PNT: 7 buys ($449.0K) and 2 sells ($217.9M).
Source: SEC EDGAR Form 4
Key Statistics (May 2022 – Dec 20, 2023)
Total Form 4 filings
9
SEC EDGAR
Insider filers
9
Insider buys (7)
$449.0K
Insider sells (2)
$217.9M
Insider sentiment
Net sellingNet insider flow of $217.4M in net selling since May 2022.
Recent PNT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 20, 2023 | Mark N Lampert | Other | Sale | 17.2M | $12.45 | $213.7M | SEC ↗ |
| Dec 1, 2022 | Joe A. Mccann | Chief Executive Officer | Purchase | 2.2K | $6.64 | $14.3K | SEC ↗ |
| Nov 28, 2022 | David Charles Lubner | Director | Purchase | 3.6K | $6.85 | $24.7K | SEC ↗ |
| Nov 28, 2022 | Gerald L. Hogue | Director | Purchase | 3.7K | $6.82 | $24.9K | SEC ↗ |
| Nov 28, 2022 | Rajesh Malik | Director | Purchase | 3.7K | $6.66 | $24.6K | SEC ↗ |
| Nov 23, 2022 | Yael Margolin | Director | Purchase | 1.7K | $6.56 | $11.2K | SEC ↗ |
| Nov 21, 2022 | Jonathan R. Goodman | Director | Purchase | 6.0K | $6.33 | $38.0K | SEC ↗ |
| Nov 21, 2022 | SILBER ALLAN C | Executive Chairman | Purchase | 50.0K | $6.22 | $311.2K | SEC ↗ |
| May 26, 2022 | Neil E. Fleshner | Chief Medical Officer | Sale | 564.2K | $7.51 | $4.2M | SEC ↗ |
Showing the 9 most recent of 9 Form 4 filings for POINT Biopharma Global Inc..
Most active PNT insiders
- David Charles Lubner1 filing
- Gerald L. Hogue1 filing
- Joe A. Mccann1 filing
- Jonathan R. Goodman1 filing
- Neil E. Fleshner1 filing
Ask anything about PNT insider activity
Use Trabud's AI agent to query POINT Biopharma Global Inc.'s Form 4 history in plain English — "Show me PNT CEO purchases this year" or compare it against any other ticker.
Open the AI agentPNT insider trading FAQ
Are POINT Biopharma Global Inc. insiders buying or selling?
POINT Biopharma Global Inc. insiders reported no open-market purchases or sales in the last 12 months. Since May 2022, Trabud has recorded 9 Form 4 filings for PNT: 7 buys ($449.0K) and 2 sells ($217.9M). Over the full record that is net selling of $217.4M.
How many insiders trade PNT stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for POINT Biopharma Global Inc.. The most recent filing was accepted on Dec 20, 2023.
Where does Trabud get PNT insider trading data?
All PNT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.